Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest

This study tests the drug cemiplimab as the first treatment for people with advanced basal cell carcinoma who have not received prior therapy. About 34 adults will receive the drug to see if it shrinks tumors. The goal is to find a more effective option for this type of skin canc…

This study tests a new combination of three drugs (zanidatamab, pembrolizumab, and chemotherapy) in people with advanced stomach or esophageal cancer that has spread. Participants must have tumors with specific markers (HER2 and PD-L1) and have not received prior treatment for me…

This study tests a new treatment for people with a type of bile duct cancer that cannot be removed by surgery. The treatment combines a procedure that uses heat to destroy cancer cells inside the bile duct with an immunotherapy drug called durvalumab, plus standard chemotherapy. …

This study looks at whether a procedure called TIPS (a shunt placed in the liver to reduce pressure) helps people with liver cancer who are taking the drugs atezolizumab and bevacizumab. About 350 participants will be observed to see how their liver function, survival, and qualit…

This study tests two drugs—fruquintinib and tislelizumab—together in people with a specific type of advanced colorectal cancer that has not spread to the liver. The cancer must be MSS/pMMR, meaning it does not respond well to standard immunotherapy alone. About 140 adults will ta…

This study tests a drug called futibatinib combined with other cancer treatments (like immunotherapy or chemotherapy) in people with colorectal cancer that has spread. The goal is to see if the combination can shrink tumors and control the disease. About 33 adults will take part,…

This study tests a combination of two drugs, enfortumab vedotin and avelumab, as a first treatment for men with advanced or metastatic penile cancer that cannot be cured by surgery. The goal is to see if the drugs shrink tumors and help patients live longer. About 25 men will tak…

This study tests a drug called ivosidenib in people with a specific type of bile duct cancer (IDH1-mutated) that has been surgically removed. After standard chemotherapy, participants take ivosidenib daily to see if it helps keep the cancer from returning. The trial involves 40 a…

This study tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a targeted radiation treatment (Y-90 SIRT) can shrink liver tumors that cannot be surgically removed. About 55 adults with intermediate-stage liver cancer will receive this combination. …

This early-phase trial tests a new combination of the immunotherapy drug tislelizumab plus standard chemotherapy (FLOT) given before surgery for people with stomach, esophageal, or gastroesophageal junction cancer that can be removed. The goal is to see if this longer pre-surgery…

This study is observing 240 lung cancer patients in Germany and Austria who are receiving the drug tislelizumab as part of their normal care. Researchers want to see how long patients live, how they feel, and what side effects occur. The goal is to learn how well the drug works o…

This study is a large registry that will collect information from up to 9,000 people in Germany with sarcoma, a rare type of cancer. The goal is to gather data on how common different sarcoma subtypes are, how they progress, and how patients respond to treatments. No new treatmen…